190 phenotypes from 11 alleles in 40 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Cd19tm1(cre)Cgn/Cd19+ Faslpr/Fastm1Cgn involves: 129P2/OlaHsd * C57BL/6 * MRL	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
Cd19tm1(cre)Cgn/Cd19+ Faslpr/Fastm1Cgn Tg(Cd4-cre)1Cwi/0 involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
	increased double-negative T cell number	J:114948
Cd19tm1(cre)Cgn/Cd19+ Fastm1Ach/Fastm1Ach involves: 129P2/OlaHsd * BALB/c	enlarged spleen	J:123556
	increased anti-nuclear antigen antibody level	J:123556
	increased immunoglobulin level	J:123556
	increased lymphocyte cell number	J:123556
Cd19tm1(cre)Cgn/Cd19+ Fastm1Cgn/Fastm1Cgn B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn	increased anti-single stranded DNA antibody level	J:114948
Faslpr-cg/Faslpr-cg CBA/KlJms-Faslpr-cg/J	abnormal hypersensitivity reaction	J:24805, J:81770
	abnormal lymph organ size	J:24805
	abnormal T cell differentiation	J:24805
	autoimmune response	J:24805, J:81770
	enlarged lymph nodes	J:24805, J:81770
	enlarged spleen	J:24805
	increased anti-nuclear antigen antibody level	J:24805
	increased autoantibody level	J:81770
	increased IgG level	J:24805, J:81770
	increased IgM level	J:24805, J:81770
	increased immunoglobulin level	J:24805
	increased spleen weight	J:81770
	premature death	J:24805
Faslpr/Faslpr AK.MRL-Faslpr	abnormal renal glomerulus morphology	J:7454
	enlarged lymph nodes	J:7454
	expanded mesangial matrix	J:7454
	glomerulonephritis	J:7454
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:7454
	increased autoantibody level	J:7454
	increased immunoglobulin level	J:7454
	increased mesangial cell number	J:7454
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
	renal glomerular immunoglobulin deposits	J:7454
Faslpr/Faslpr B6.Cg-Apoetm1Unc Faslpr	normal cardiovascular system phenotype	J:121671
Faslpr/Faslpr B6.MRL-Faslpr	abnormal renal glomerulus morphology	J:7454
	decreased interleukin-2 secretion	J:6638
	enlarged lymph nodes	J:6638, J:7454, J:135036
	enlarged spleen	J:135036
	expanded mesangial matrix	J:7454
	glomerulonephritis	J:7454, J:135036
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:6638, J:135036
	increased autoantibody level	J:7454, J:135036
	increased double-negative T cell number	J:135036
	increased immunoglobulin level	J:7454
	increased mesangial cell number	J:7454
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
	premature death	J:6638, J:7454, J:135036
	renal glomerular immunoglobulin deposits	J:7454, J:135036
Faslpr/Faslpr B6.MRL-Faslpr/J	abnormal hepatocyte morphology	J:135830
	abnormal kidney morphology	J:132217
	abnormal liver physiology	J:120559, J:135830
	abnormal NK cell physiology	J:115033
	abnormal renal glomerulus basement membrane morphology	J:132217
	abnormal splenic cell ratio	J:132217
	brain inflammation	J:120427
	CNS inflammation	J:120427
	decreased B cell apoptosis	J:135830
	decreased hepatocyte apoptosis	J:135830
	demyelination	J:120427
	enlarged lymph nodes	J:119584
	focal hepatic necrosis	J:135830
	increased anti-double stranded DNA antibody level	J:132217
	increased anti-histone antibody level	J:132217
	increased anti-nuclear antigen antibody level	J:132217
	increased anti-single stranded DNA antibody level	J:132217
	increased autoantibody level	J:132217
	increased follicular B cell number	J:132217
	increased immature B cell number	J:132217
	increased marginal zone B cell number	J:132217
	increased renal glomerulus apoptosis	J:132217
	increased splenocyte number	J:132217
	increased susceptibility to bacterial infection	J:136745
	increased susceptibility to Picornaviridae infection	J:120427
	increased transitional stage B cell number	J:132217
	lymph node hyperplasia	J:132217
Faslpr/Faslpr C3.MRL-Faslpr	abnormal interleukin level	J:8267
	abnormal T cell morphology	J:8267
	abnormal T cell physiology	J:8267
	abnormal T cell proliferation	J:8267
	abnormal vagina weight	J:114219
	decreased apoptosis	J:114219
	decreased neuron apoptosis	J:124252
	normal endocrine/exocrine gland phenotype	J:1028
	lacrimal gland atrophy	J:1028
	lacrimal gland inflammation	J:1028
	salivary gland inflammation	J:1028
Faslpr/Faslpr C3.MRL-Faslpr/J	abnormal airway responsiveness	J:106288
	abnormal B cell activation	J:7454
	abnormal renal glomerulus morphology	J:7454
	abnormal T cell morphology	J:7454
	decreased eosinophil cell number	J:106288
	decreased interleukin-2 secretion	J:7454
	enlarged lymph nodes	J:7454
	expanded mesangial matrix	J:7454
	glomerulonephritis	J:7454
	normal immune system phenotype	J:7454
	increased anti-double stranded DNA antibody level	J:7454
	increased anti-nuclear antigen antibody level	J:7454
	increased apoptosis	J:106288
	increased autoantibody level	J:7454
	increased immunoglobulin level	J:7454
	increased mesangial cell number	J:7454
	lymph node hemorrhage	J:7454
	lymph node hyperplasia	J:7454
	lymph node necrosis	J:7454
	normal mortality/aging	J:120650
	premature death	J:7454
	renal glomerular immunoglobulin deposits	J:7454
Faslpr/Faslpr involves: 129P2/OlaHsd * MRL	abnormal kidney morphology	J:45448
	abnormal renal glomerulus morphology	J:45448
	enlarged lymph nodes	J:26250
	glomerulonephritis	J:45448
	increased blood urea nitrogen level	J:45448
	increased double-negative T cell number	J:26250
	increased gamma-delta T cell number	J:26250
	increased urine protein level	J:45448
	kidney inflammation	J:45448
	premature death	J:26250
Faslpr/Faslpr involves: C3H * MRL/Mp	abnormal stria vascularis morphology	J:1060, J:34296
	abnormal stria vascularis vasculature morphology	J:34296
	autoimmune response	J:1060
	increased anti-nuclear antigen antibody level	J:34296
	increased or absent threshold for auditory brainstem response	J:1060, J:34296
	increased spleen weight	J:34296
	increased susceptibility to systemic lupus erythematosus	J:34296
	increased susceptibility to type III hypersensitivity reaction	J:34296
Faslpr/Faslpr involves: C57BL/6 * MRL/Mp	enlarged spleen	J:73396
	increased anti-double stranded DNA antibody level	J:73396
	increased anti-single stranded DNA antibody level	J:73396
	increased IgA level	J:73396
	increased IgG1 level	J:73396
	increased IgG2a level	J:73396
	increased IgG2b level	J:73396
	increased IgG3 level	J:73396
	increased IgM level	J:73396
	lymph node hyperplasia	J:73396
Faslpr/Faslpr involves: MRL/Mp	decreased macrophage apoptosis	J:154647
	increased susceptibility to bacterial infection	J:50903
	increased susceptibility to induced morbidity/mortality	J:50903
Faslpr/Faslpr MRL-Faslpr	abnormal T-helper 2 physiology	J:6257
	enlarged lymph nodes	J:126261
	glomerulonephritis	J:126261
	increased anti-double stranded DNA antibody level	J:126261
	increased anti-nuclear antigen antibody level	J:126261
	increased blood urea nitrogen level	J:126261
	increased IgG level	J:126261
	increased IgM level	J:126261
	increased immunoglobulin level	J:6257
	increased spleen weight	J:126261
	vascular inflammation	J:126261
Faslpr/Faslpr MRL.Cg-Irf1tm1Mak Faslpr	abnormal skin condition	J:114771
	epidermal necrosis	J:114771
	glomerulonephritis	J:114771
	increased anti-double stranded DNA antibody level	J:114771
	increased urine protein level	J:114771
	kidney failure	J:114771
	premature death	J:114771
	renal glomerular immunoglobulin deposits	J:114771
	skin lesions	J:114771
Faslpr/Faslpr MRL.Cg-Tnfrsf9tm1Byk Faslpr	premature death	J:127197
	skin lesions	J:127197
Faslpr/Faslpr MRL/Mp-Agtpbp1atms Faslpr	enlarged lymph nodes	J:103944
	enlarged spleen	J:103944
	enlarged thymus	J:103944
	increased body weight	J:103944
	increased tumor incidence	J:103944
	ruffled hair	J:103944
Faslpr/Faslpr MRL/Mp-Faslpr	abnormal B cell morphology	J:108760
	abnormal B cell receptor editing	J:131138
	abnormal cardiovascular system physiology	J:27634
	abnormal circulating protein level	J:27634
	abnormal coronary artery morphology	J:27634
	abnormal cytotoxic T cell physiology	J:7488
	abnormal gland morphology	J:18512
	abnormal glomerular capillary endothelium morphology	J:28885
	abnormal glomerular capillary morphology	J:28885
	abnormal immune system organ morphology	J:28885
	abnormal immune system physiology	J:28885
	abnormal interleukin level	J:8267
	abnormal lymph node cell ratio	J:6257
	abnormal lymph node morphology	J:27634
	abnormal marginal zone B cell morphology	J:131138
	abnormal submandibular gland morphology	J:18512
	abnormal T cell morphology	J:8267, J:108760
	abnormal T cell physiology	J:8267
	abnormal T cell proliferation	J:8267
	abnormal T-helper 2 physiology	J:6257
	abnormal thymus medulla morphology	J:28885
	abnormal thyroid follicle morphology	J:28171
	abnormal thyroid gland morphology	J:28171
	abnormal type III hypersensitivity reaction	J:28885
	blood vessel inflammation	J:28885
	decreased interleukin-2 secretion	J:6638, J:7488
	normal endocrine/exocrine gland phenotype	J:18512
	enlarged lymph nodes	J:13757, J:27634, J:28885, J:108760
	enlarged Peyer's patches	J:28885
	enlarged spleen	J:28885
	enlarged thymus	J:13757
	glomerular crescent	J:28885
	glomerulonephritis	J:13757, J:27634, J:28885
	increased anti-double stranded DNA antibody level	J:6257, J:27634, J:131138
	increased anti-erythrocyte antigen antibody level	J:27634
	increased anti-nuclear antigen antibody level	J:27634, J:28885
	increased anti-single stranded DNA antibody level	J:27634
	increased autoantibody level	J:28885
	increased circulating serum albumin level	J:28885
	increased circulating total protein level	J:28885
	increased IgA level	J:28885
	increased IgG1 level	J:13757, J:28885
	increased IgG2a level	J:13757, J:28885
	increased IgG2b level	J:28885
	increased IgG level	J:27634
	increased IgM level	J:28885
	increased immunoglobulin level	J:6257, J:13757, J:28885
	increased kidney cell proliferation	J:27634
	increased mesangial cell number	J:28885
	increased renal glomerulus basement membrane thickness	J:28885
	increased susceptibility to autoimmune disorder	J:108760
	increased thymus weight	J:28885
	increased urine protein level	J:28885
	joint swelling	J:27634
	lacrimal gland inflammation	J:18512
	lymph node hemorrhage	J:27634
	lymph node hyperplasia	J:27634
	lymph node necrosis	J:27634
	premature death	J:13757, J:27634, J:28885
	renal cast	J:28885
	renal glomerular immunoglobulin deposits	J:13757, J:27634
	renal glomerular protein deposits	J:27634
	salivary gland inflammation	J:18512
	skin lesions	J:28885
submandibular gland inflammation	J:21965
thymus atrophy	J:27634
thymus cortex atrophy	J:13757, J:28885
thyroid gland inflammation	J:28171
Faslpr/Faslpr MRL/MpJ-Faslpr	abnormal leukocyte adhesion	J:126009
	abnormal leukocyte morphology	J:126009
	autoimmune response	J:125114
	blood vessel inflammation	J:137066
	decreased activated T cell number	J:137066
	decreased B cell number	J:137066
	decreased CD4-positive, alpha-beta T cell number	J:137066
	decreased CD8-positive, alpha-beta T cell number	J:137066
	enlarged lymph nodes	J:137066
	enlarged spleen	J:137066
	glomerulonephritis	J:125114, J:132514, J:137066
	impaired leukocyte tethering or rolling	J:126009
	increased anti-nuclear antigen antibody level	J:137066
	increased autoantibody level	J:137066
	increased double-negative T cell number	J:137066
	increased immunoglobulin level	J:125114
	premature death	J:125114, J:137066
	renal glomerular immunoglobulin deposits	J:125114
Faslpr/Faslpr MRL/MpJ-Faslpr/J	abnormal conjunctival epithelium morphology	J:123192
	abnormal enzyme/coenzyme activity	J:109815
	abnormal immunoglobulin level	J:122315
	abnormal kidney physiology	J:127199
	abnormal myocardium layer morphology	J:14151
	abnormal renal glomerulus morphology	J:7454, J:127199
	abnormal spatial learning	J:14151
	abnormal stria vascularis morphology	J:3638
	abnormal strial intermediate cell morphology	J:3638
	albuminuria	J:122315
	CNS inflammation	J:14151
	conjunctivitis	J:123192
	cortical renal glomerulopathies	J:122315
	decreased IgG level	J:122315
	decreased immature B cell number	J:122315
	decreased marginal zone B cell number	J:122315
	decreased mature B cell number	J:122315
	decreased spleen germinal center number	J:122315
	decreased transitional stage B cell number	J:122315
	dilated renal glomerular capsule	J:122315
	enlarged lymph nodes	J:7454, J:92084
	expanded mesangial matrix	J:127199
	glomerular crescent	J:122315
	glomerulonephritis	J:7454, J:92084, J:122315, J:127199
	impaired coordination	J:14151
	increased anti-double stranded DNA antibody level	J:7454, J:92084, J:122315
	increased anti-nuclear antigen antibody level	J:7454, J:14151, J:92084, J:111811
	increased autoantibody level	J:14151, J:92084
	increased IgG level	J:92084
	increased immunoglobulin level	J:7454, J:122315
	increased mesangial cell number	J:127199
	increased neutrophil cell number	J:127199
	increased or absent threshold for auditory brainstem response	J:3638
	increased plasma cell number	J:122315
	increased susceptibility to systemic lupus erythematosus	J:92084
	increased urine protein level	J:92084, J:122315
	lymph node hemorrhage	J:7454
	lymph node necrosis	J:7454
	podocyte foot process effacement	J:127199
	premature death	J:7454
	renal glomerulus hypertrophy	J:122315
	salivary gland inflammation	J:92084
	vascular inflammation	J:127199
	normal vision/eye phenotype	J:123192
Faslpr/Faslpr NOD.MRL(B6)-Faslpr	decreased susceptibility to autoimmune diabetes	J:64051
Faslpr/Faslpr NOD.MRL-Faslpr	decreased susceptibility to autoimmune diabetes	J:78679
Faslpr/Fastm1.1Cgn involves: C57BL/6 * MRL	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
Faslpr/Fastm1Cgn Tg(Cd4-cre)1Cwi/0 involves: C57BL/6 * DBA/2 * MRL	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
	increased double-negative T cell number	J:114948
Fasm1Btlr/Fasm1Btlr C57BL/6J-Fasm1Btlr	decreased CD4-positive, alpha-beta T cell number	J:216052
	decreased CD8-positive, alpha-beta T cell number	J:216052
	increased neutrophil cell number	J:216052
	increased NK cell number	J:216052
Fasm2Btlr/Fasm2Btlr C57BL/6J-Fasm2Btlr	increased central memory CD4-positive, alpha-beta T cell number	J:271891
	increased effector memory CD4-positive, alpha-beta T cell number	J:271891
Fastheo/Fastheo either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu)	enlarged lymph nodes	J:104190
	increased anti-nuclear antigen antibody level	J:104190
Fastm1.1(ALPP)Chnd/Fastm1.1(ALPP)Chnd involves: C57BL/6 * SJL	no abnormal phenotype detected	J:101977
Fastm1.1Cgn/Fastm1.1Cgn involves: C57BL/6	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
Fastm1Ach/Fastm1Ach Tg(GZMB-cre)1Jcb/? involves: C57BL/6 * FVB/N	increased anti-nuclear antigen antibody level	J:123556
	increased double-positive T cell number	J:123556
Fastm1Ach/Fastm1Ach Tg(Itgax-cre,-EGFP)4097Ach/? Not Specified	abnormal liver morphology	J:123556
	abnormal spleen morphology	J:123556
	abnormal spleen periarteriolar lymphoid sheath morphology	J:123556
	decreased apoptosis	J:123556
	enlarged spleen	J:123556
	increased anti-nuclear antigen antibody level	J:123556
	increased dendritic cell number	J:123556
	increased IgG level	J:123556
	increased IgM level	J:123556
	increased immunoglobulin level	J:123556
Fastm1Ach/Fastm1Ach Tg(Lck-cre)548Jxm/? involves: C57BL/6 * CBA	increased anti-nuclear antigen antibody level	J:123556
	increased double-positive T cell number	J:123556
Fastm1Cgn/Fastm1Cgn C57BL/6-Fastm1Cgn	normal immune system phenotype	J:114948
Fastm1Cgn/Fastm1Cgn Cd19tm1(cre)Cgn/Cd19+ Tg(Cd4-cre)1Cwi/0 B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn	increased anti-single stranded DNA antibody level	J:114948
Fastm1Cgn/Fastm1Cgn Mogtm1(cre)Gkl/Mog+ involves: C57BL/6	decreased susceptibility to experimental autoimmune encephalomyelitis	J:114741
	normal immune system phenotype	J:114741
Fastm1Cgn/Fastm1Cgn Tg(Cd4-cre)1Cwi/0 B6.Cg-Tg(Cd4-cre)1Cwi Fastm1Cgn	abnormal immune system cell morphology	J:114948
	abnormal immune system organ morphology	J:114948
	abnormal thymus involution	J:114948
	alveolitis	J:114948
	decreased B cell number	J:114948
	decreased T cell number	J:114948
	enlarged spleen	J:114948
	increased activated T cell number	J:114948
	increased anti-single stranded DNA antibody level	J:114948
	increased double-negative T cell number	J:114948
	increased inflammatory response	J:114948
	increased memory T cell number	J:114948
	increased T cell apoptosis	J:114948
	kidney inflammation	J:114948
	liver inflammation	J:114948
	lung inflammation	J:114948
	lymph node hypoplasia	J:114948
	premature death	J:114948
	pulmonary fibrosis	J:114948
	spleen hypoplasia	J:114948
	weight loss	J:114948
Fastm1Cgn/Fastm1Cgn Tg(Lck-cre)I57Jxm/0 B6.Cg-Fastm1Cgn Tg(Lck-cre)I57Jxm	lymph node hypoplasia	J:114948
Fastm1Cgn/Fastm1Cgn Tg(Mx1-cre)1Cgn/0 B6.Cg-Fastm1Cgn Tg(Mx1-cre)1Cgn	abnormal immune system morphology	J:114948
	enlarged lymph nodes	J:114948
	enlarged spleen	J:114948
Fastm1Dlo/Fastm1Dlo involves: 129P2/OlaHsd * C57BL/6	abnormal apoptosis	J:90750
	abnormal thymus involution	J:90750
	enlarged lymph nodes	J:31847
	enlarged spleen	J:31847
	increased immunoglobulin level	J:31847
Fastm1Osa/Fastm1Osa involves: 129P2/OlaHsd * C57BL/6	abnormal hepatocyte morphology	J:64296
	abnormal hypersensitivity reaction	J:32125, J:64296
	abnormal lymph organ size	J:64296
	abnormal T cell clonal deletion	J:32125
	enlarged lymph nodes	J:32125, J:64296
	enlarged spleen	J:32125, J:64296
	increased anti-double stranded DNA antibody level	J:32125
	increased anti-single stranded DNA antibody level	J:32125
	increased autoantibody level	J:32125
	increased B cell number	J:32125
	increased IgG1 level	J:32125
	increased IgG2a level	J:32125
	increased IgG2b level	J:32125
	increased IgG3 level	J:32125
	increased IgG level	J:32125
	increased leukocyte cell number	J:32125
	increased lymphocyte cell number	J:32125, J:64296
	increased susceptibility to parasitic infection	J:81397
	liver hyperplasia	J:64296
	lymphoid hyperplasia	J:64296
	premature death	J:64296